RiboX Therapeutics
Founded 2021 · $110.0M raised
- Founded
- 2021
- Business Model
- B2B
- Website
- riboxtx.com
- Total Funding
- $110.0M
- Last Round
- $110.0M Series B
- Rounds
- 1
About
RiboX Therapeutics is a biotechnology company discovering and developing fully engineered circular RNA (circRNA) therapeutics, a class of RNA medicines designed to overcome the stability and durability limitations of conventional mRNA drugs. Cofounded in 2021 by Drs. Ling-Ling Chen, Dan Peer, and Weiyi Zhang, the company operates across Shanghai, Princeton (New Jersey, US), and Rehovot (Israel). In 2024 RiboX became the first company to receive FDA IND clearance for a circular RNA therapy, RXRG001, targeting radiation-induced xerostomia and hyposalivation, and has since dosed its first patient in a Phase I/IIa trial.
Summary
RiboX Therapeutics is a Biotech company, founded in 2021. It has raised $110.0M in total across 1 round. Investors include Qiming VP, Boehringer Ingelheim Venture Fund and Vivo Capital.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Unknown
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.